A Traditional Feasibility study of Gemcitabine, Cisplatin, and 90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma Save

Date Added
July 21st, 2015
PRO Number
Pro00043494
Researcher
Samuel Cooper
Keywords
Cancer, Cancer/Gastrointestinal
Summary

This study is for adult patients with intrahepatocellular carcinoma. The purpose of this research study is to evaluate the safety and maximum tolerated dose of Gemcitabine and Cisplatin with 90Y TARE. Subjects will have screening tests to determine if he or she is eligible to participate in this study. If the subject is eligible and wishes to enroll, he or she will begin chemotherapy treatment with Gemcitabine and Cisplatin. During the chemotherapy treatment, the patient will receive the 90Y TARE treatment. Study treatment will last up to 8 cycles; each cycle is 21 days. Subjects will be followed after treatment is completed for up to 6 years after treatment started.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login